VTRS

SEC source: 0000899243-20-034523 · doc4.xml · nonDerivative · entry 1

KILTS JAMES M · CIK 0001025094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,905

F1 · price: Represents the weighted average price of the reporting person's acquisition of 27,736 shares of common stock in transactions ranging from $17.57 to $17.73. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-006363 · doc5.xml · nonDerivative · entry 2

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Irrevocable Trust

Disclosed balance after: 460,319

F1 · kind: This transaction involved a gift of securities by the reporting person to an irrevocable trust for the benefit of his spouse and children on December 16, 2020. The reporting person's spouse is the trustee of the trust.

SEC source: 0000899243-21-006363 · doc5.xml · nonDerivative · entry 1

Malik Rajiv · CIK 0001388111 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction involved a gift of securities by the reporting person to an irrevocable trust for the benefit of his spouse and children on December 16, 2020. The reporting person's spouse is the trustee of the trust.

SEC source: 0000950170-24-117437 · ownership.xml · nonDerivative · entry 1

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,419

F1 · kind: These transactions were executed by the reporting person's investment advisors in managed accounts as part of the investment advisors' implementation and continued execution of managed investment strategies involving the securities of multiple issuers.

F2 · price: Based on information provided by the investment advisor; additional information, including the price range, if any, is unavailable.

SEC source: 0000899243-20-032185 · doc4.xml · derivative · entry 1

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600,000

Underlying: Common Stock · 1,600,000 shares

Expires not disclosed

F1 · security: Each Each performance restricted stock unit ("PRSU") represents the right to receive one share of common stock of Viatris Inc. The PRSUs were granted on November 23, 2020 and are divided into five separate vesting tranches requiring share price appreciation and shareholder returns (including dividends and other distributions) of 25%, 50%, 75%, 100% and 150% from the date of grant through December 30, 2025. In the case of the first three tranches, the PRSUs are subject to a retention requirement through the first anniversary of achieving the shareholder return goal, and in the case of the final two tranches, the PRSUs are subject to a retention requirement through the term of the award. The PRSUs would vest in full upon termination of employment without cause, resignation for good reason, disability or death.

F1 · price: Each Each performance restricted stock unit ("PRSU") represents the right to receive one share of common stock of Viatris Inc. The PRSUs were granted on November 23, 2020 and are divided into five separate vesting tranches requiring share price appreciation and shareholder returns (including dividends and other distributions) of 25%, 50%, 75%, 100% and 150% from the date of grant through December 30, 2025. In the case of the first three tranches, the PRSUs are subject to a retention requirement through the first anniversary of achieving the shareholder return goal, and in the case of the final two tranches, the PRSUs are subject to a retention requirement through the term of the award. The PRSUs would vest in full upon termination of employment without cause, resignation for good reason, disability or death.

F1 · derivative.exercise_date: Each Each performance restricted stock unit ("PRSU") represents the right to receive one share of common stock of Viatris Inc. The PRSUs were granted on November 23, 2020 and are divided into five separate vesting tranches requiring share price appreciation and shareholder returns (including dividends and other distributions) of 25%, 50%, 75%, 100% and 150% from the date of grant through December 30, 2025. In the case of the first three tranches, the PRSUs are subject to a retention requirement through the first anniversary of achieving the shareholder return goal, and in the case of the final two tranches, the PRSUs are subject to a retention requirement through the term of the award. The PRSUs would vest in full upon termination of employment without cause, resignation for good reason, disability or death.

F1 · derivative.expiration_date: Each Each performance restricted stock unit ("PRSU") represents the right to receive one share of common stock of Viatris Inc. The PRSUs were granted on November 23, 2020 and are divided into five separate vesting tranches requiring share price appreciation and shareholder returns (including dividends and other distributions) of 25%, 50%, 75%, 100% and 150% from the date of grant through December 30, 2025. In the case of the first three tranches, the PRSUs are subject to a retention requirement through the first anniversary of achieving the shareholder return goal, and in the case of the final two tranches, the PRSUs are subject to a retention requirement through the term of the award. The PRSUs would vest in full upon termination of employment without cause, resignation for good reason, disability or death.

SEC source: 0000899243-20-032088 · doc4.xml · derivative · entry 4

GOETTLER MICHAEL · CIK 0001745691 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,975

Underlying: Common Stock · 119,975 shares

Expires not disclosed

F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 27, 2023.

F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 27, 2023.

SEC source: 0000899243-20-032088 · doc4.xml · derivative · entry 3

GOETTLER MICHAEL · CIK 0001745691 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,958

Underlying: Common Stock · 53,958 shares

Expires not disclosed

F3 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 28, 2022.

F3 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 28, 2022.

SEC source: 0000899243-20-032088 · doc4.xml · derivative · entry 2

GOETTLER MICHAEL · CIK 0001745691 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,499

Underlying: Common Stock · 3,499 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 22, 2021.

F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 22, 2021.

SEC source: 0000899243-20-032087 · doc4.xml · derivative · entry 2

Narula Sanjeev · CIK 0001820590 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,246

Underlying: Common Stock · 21,246 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 27, 2023.

F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents the right to receive one share of common stock of Viatris. The RSUs will vest on February 27, 2023.

SEC source: 0000899243-20-031560 · doc4.xml · nonDerivative · entry 1

KILTS JAMES M · CIK 0001025094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,169

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3 · balance_after: Includes 280 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 11

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F12 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F12 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F13 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F13 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 10

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F11 · derivative.exercise_date: These options will vest on March 2, 2021.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 9

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Underlying: Common Stock · 4,352 shares

Expires 2029-03-01

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F10 · derivative.exercise_date: These options vested on March 2, 2020.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 8

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,984

Underlying: Common Stock · 2,984 shares

Expires 2028-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on March 2, 2019.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 7

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,928

Underlying: Common Stock · 2,928 shares

Expires 2027-03-03

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 3, 2018.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 6

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,788

Underlying: Common Stock · 2,788 shares

Expires 2026-02-17

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on February 17, 2017.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 5

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,603

Underlying: Common Stock · 2,603 shares

Expires 2025-11-17

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on May 1, 2016.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 4

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,974

Underlying: Common Stock · 2,974 shares

Expires 2024-04-11

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on April 11, 2015.

SEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 3

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,623

Underlying: Common Stock · 6,623 shares

Expires 2023-05-28

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · derivative.exercise_date: These options vested on May 28, 2014.

SEC source: 0000899243-20-031573 · doc4.xml · nonDerivative · entry 2

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 74,000

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031573 · doc4.xml · nonDerivative · entry 1

HIGGINS MELINA E · CIK 0001162304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,131

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 9

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F11 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F11 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F12 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F12 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 8

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F10 · derivative.exercise_date: These options will vest on March 2, 2021

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 7

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Underlying: Common Stock · 4,352 shares

Expires 2029-03-01

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on March 2, 2020.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 6

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,984

Underlying: Common Stock · 2,984 shares

Expires 2028-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 2, 2019.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 5

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,928

Underlying: Common Stock · 2,928 shares

Expires 2027-03-03

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on March 3, 2018.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 4

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,788

Underlying: Common Stock · 2,788 shares

Expires 2026-02-17

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on February 17, 2017.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 3

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,603

Underlying: Common Stock · 2,603 shares

Expires 2025-11-17

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on May 1, 2016.

SEC source: 0000899243-20-031577 · doc4.xml · derivative · entry 2

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,974

Underlying: Common Stock · 2,974 shares

Expires 2024-04-11

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · derivative.exercise_date: These options vested on April 11, 2015.

SEC source: 0000899243-20-031577 · doc4.xml · nonDerivative · entry 1

DIMICK NEIL F · CIK 0001248380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,263

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 9

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F12 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F12 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F13 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F13 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 8

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F11 · derivative.exercise_date: These options will vest on March 2, 2021.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 7

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Underlying: Common Stock · 4,352 shares

Expires 2029-03-01

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F10 · derivative.exercise_date: These options vested on March 2, 2020.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 6

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,984

Underlying: Common Stock · 2,984 shares

Expires 2028-03-02

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on March 2, 2019.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 5

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,928

Underlying: Common Stock · 2,928 shares

Expires 2027-03-03

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 3, 2018.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 4

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,788

Underlying: Common Stock · 2,788 shares

Expires 2026-02-17

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on February 17, 2017.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 3

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,603

Underlying: Common Stock · 2,603 shares

Expires 2025-11-17

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on May 1, 2016.

SEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 2

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,974

Underlying: Common Stock · 2,974 shares

Expires 2024-04-11

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on April 11, 2015.

SEC source: 0000899243-20-031574 · doc4.xml · nonDerivative · entry 1

PARRISH MARK W · CIK 0001236452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,313

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3 · balance_after: Includes 18 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 8

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires not disclosed

F10 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F11 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on June 24, 2021.

F11 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on June 24, 2021.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 7

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,776

Underlying: Common Stock · 82,776 shares

Expires 2026-02-17

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on February 17, 2019.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 6

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,235

Underlying: Common Stock · 63,235 shares

Expires 2025-11-17

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 4, 2018.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 5

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,952

Underlying: Common Stock · 58,952 shares

Expires 2024-03-05

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on March 5, 2017.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 4

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,236

Underlying: Common Stock · 3,236 shares

Expires 2023-03-06

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on March 6, 2016.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 3

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,266

Underlying: Common Stock · 4,266 shares

Expires 2022-02-22

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on February 22, 2015.

SEC source: 0000899243-20-031568 · doc4.xml · derivative · entry 2

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,413

Underlying: Common Stock · 4,413 shares

Expires 2021-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · derivative.exercise_date: These options vested on March 2, 2014.

SEC source: 0000899243-20-031568 · doc4.xml · nonDerivative · entry 1

COURY ROBERT J · CIK 0001197543 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,383,587

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 8

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F11 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F11 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F12 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F12 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 7

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F10 · derivative.exercise_date: These options will vest on March 2, 2021.

SEC source: 0000899243-20-031554 · doc4.xml · derivative · entry 6

KORMAN HARRY · CIK 0001197548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Underlying: Common Stock · 4,352 shares

Expires 2029-03-01

F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on March 2, 2020.